Results 161 to 170 of about 112,964 (206)

Cisplatin resistance in human cancers

Pharmacology & Therapeutics, 1991
Cancer chemotherapeutic agents primarily act by damaging cellular DNA directly or indirectly. Tumor cells, in contrast to normal cells, respond to cisplatin with transient gene expression to protect and/or repair their chromosomes. Repeated cisplatin treatments results in a stable resistant cell line with enhanced gene expression but lacking gene ...
K J, Scanlon, M, Kashani-Sabet, T, Tone, T, Funato   +3 more
openaire   +2 more sources

Mechanisms of cellular resistance to cisplatin

Medical Oncology and Tumor Pharmacotherapy, 1988
Treatment of cancer patients often fails because of the resistance in the tumor to chemotherapeutic drugs. A better understanding of mechanisms which are active in resistant cells might lead to measures to circumvent the resistance. This review deals with the mechanisms of action of cisplatin (CDDP) and the various causes for CDDP resistance in the ...
G A, Hospers, N H, Mulder, E G, De Vries
openaire   +2 more sources

Cisplatin resistance and oncogenes - a review

Anti-Cancer Drugs, 2000
Cisplatin is among the most widely used broadly active cytotoxic anticancer drugs; however, its clinical efficacy is often limited by primary or the development of secondary resistance. Several mechanisms have been implicated in cisplatin resistance, including reduced drug uptake, increased cellular thiol/folate levels and increased DNA repair.
W, Dempke, W, Voigt, A, Grothey, B T, Hill, H J, Schmoll   +4 more
openaire   +2 more sources

Mechanisms of resistance to cisplatin and carboplatin

Critical Reviews in Oncology/Hematology, 2007
While cisplatin and carboplatin are active versus most common cancers, epithelial malignancies are incurable when metastatic. Even if an initial response occurs, acquired resistance due to mutations and epigenetic events limits efficacy. Resistance may be due to excess of a resistance factor, to saturation of factors required for tumor cell killing, or
openaire   +2 more sources

Cisplatin Resistance Associated with PARP Hyperactivation

Cancer Research, 2013
Abstract Non–small cell lung carcinoma patients are frequently treated with cisplatin (CDDP), most often yielding temporary clinical responses. Here, we show that PARP1 is highly expressed and constitutively hyperactivated in a majority of human CDDP-resistant cancer cells of distinct histologic origin.
Michels, J., Vitale, I., Galluzzi, L., Adam, J., Olaussen, K., Kepp, O., Senovilla, L., Talhaoui, I., Guegan, J., Enot, D., Talbot, M., Robin, A., Girard, Pascal, Orear, C., Lissa, D., Sukkurwala, A., Garcia, P., Behnam-Motlagh, P., Kohno, K., Wu, G., Brenner, Catherine, Dessen, P., Saparbaev, M., Soria, J.-C., Castedo, M., Kroemer, G.   +25 more
openaire   +3 more sources

Mechanisms of resistance to cisplatin

1991
A number of changes have been detected in cisplatin-resistant cells, some of which are likely to be directly involved in the mechanism of resistance. The four most cited mechanisms are reduced accumulation, increased glutathione, increased metallothionein, and enhanced DNA repair.
openaire   +2 more sources

Overcoming cisplatin resistance in chemotherapy by biomineralization

Chemical Communications, 2013
Nano-solidified intermedias (NSI) of cisplatin were prepared via biomineralization and applied to reverse the drug resistance of cancers in vitro and in vivo by an alternative internalization pathway.
Wei, Chen, Yun, Xiao, Xueyao, Liu, Yanhong, Chen, Jiaojiao, Zhang, Xurong, Xu, Ruikang, Tang   +6 more
openaire   +2 more sources

The role of microRNA in cisplatin resistance or sensitivity

Expert Opinion on Therapeutic Targets, 2020
Cisplatin is a chemotherapy drug that has been used to treat a number of cancers for decades, and is still one of the most commonly used anti-cancer agents. However, some patients do not respond to cisplatin while other patients who were originally sensitive to cisplatin eventually develop chemoresistance, leading to treatment failure or/and tumor ...
Shanshan, Wang, Ming-Yue, Li, Yi, Liu, Alexander C, Vlantis, Jason Yk, Chan, Lingbin, Xue, Bao-Guang, Hu, Shucai, Yang, Mo-Xian, Chen, Shaoming, Zhou, Wei, Guo, Xianhai, Zeng, Shuqi, Qiu, C Andrew, van Hasselt, Michael Cf, Tong, George G, Chen   +15 more
openaire   +2 more sources

Resistance to cisplatin.

Anti-cancer drug design, 1999
Resistance to cis-diamminedichloroplatinum(II) (cisplatin), a DNA damaging agent, is a major obstacle for its clinical effectiveness. Multiple mechanisms may be involved in cisplatin resistance. Frequently cited mechanisms include reduced accumulation, elevated levels of glutathione (GSH) and metallothionein, and enhanced DNA repair.
S, Akiyama, Z S, Chen, T, Sumizawa, T, Furukawa   +3 more
openaire   +1 more source

Mechanisms of acquired resistance to cisplatin

1994
Since the discovery of the antitumor activity in rodents of cisplatin (cis-diamminedichloroplatinum(II)) in 1968 [1], the use of this drug in treating human disease has grown to the point where it is now one of the most widely used antineoplastics. Cisplatin has an established role in the treatment of testicular, ovarian, bladder, germ cell, and head ...
openaire   +2 more sources